HC Wainwright & Co. Maintains Buy on Actinium Pharma, Lowers Price Target to $50
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Actinium Pharma (AMEX:ATNM) but lowers the price target from $53 to $50.

August 15, 2023 | 10:48 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Actinium Pharma's price target has been lowered from $53 to $50 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target could potentially indicate a less optimistic outlook for the company's stock, which may impact investor sentiment. However, the maintained 'Buy' rating suggests that the analyst still sees potential upside, which could balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100